Ameriprise
GPCR icon

Ameriprise’s Structure Therapeutics GPCR Stock Holding History

Ameriprise’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.4M Buy
230,514
+10,998
+5% +$487K ﹤0.01% 1900
2026
Q1 		$10.6M Sell
219,516
-66,002
-23% -$4.52M ﹤0.01% 1885
2025
Q4 		$19.9M Sell
285,518
-938,626
-77% -$38.3M ﹤0.01% 1420
2025
Q3 		$34.3M Sell
1,224,144
-364,054
-23% -$7.25M 0.01% 1087
2025
Q2 		$32.9M Buy
1,588,198
+106,389
+7% +$2.34M 0.01% 1083
2025
Q1 		$25.7M Buy
1,481,809
+61,757
+4% +$1.51M 0.01% 1167
2024
Q4 		$38.5M Buy
1,420,052
+322,601
+29% +$11.4M 0.01% 974
2024
Q3 		$48.2M Buy
1,097,451
+690,607
+170% +$26.7M 0.01% 871
2024
Q2 		$16M Buy
406,844
+316,187
+349% +$13M ﹤0.01% 1412
2024
Q1 		$3.89M Buy
90,657
+27,900
+44% +$1.18M ﹤0.01% 2520
2023
Q4 		$2.56M Buy
+62,757
New +$3.6M ﹤0.01% 2754

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Ameriprise's GPCR Position: Q2 2026 in Review

Ameriprise increased its Structure Therapeutics (GPCR) stake by 5% in Q2 2026, buying an estimated $487K and bringing the position to 230,514 shares worth $12.4M. The position accounts for ﹤0.01% of the portfolio, ranked #1900.

Ameriprise first reported a position in GPCR in Q4 2023 and has held it in 11 quarters since. The position peaked at $48.2M in Q3 2024. 192 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Ameriprise held 230,514 shares of Structure Therapeutics worth $12.4M as of Q2 2026.
  • Ameriprise bought 10,998 Structure Therapeutics shares in Q2 2026, an estimated $487K.
  • Structure Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1900 holding.
  • Ameriprise first reported a position in Structure Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Ameriprise's Structure Therapeutics position peaked at $48.2M in Q3 2024.
  • 192 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.